|
1
|
Trojan J, Zangos S and Schnitzbauer AA:
Diagnostics and treatment of hepatocellular carcinoma in 2016:
Standards and developments. Visc Med. 32:116–120. 2016.PubMed/NCBI
|
|
2
|
Lencioni R, Petruzzi P and Crocetti L:
Chemoembolization of hepatocellular carcinoma. Semin Intervent
Radiol. 30:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim HY and Park JW: Clinical trials of
combined molecular targeted therapy and locoregional therapy in
hepatocellular carcinoma: Past, present, and future. Liver Cancer.
3:9–17. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Furuse J, Ishii H, Nakachi K, Suzuki E,
Shimizu S and Nakajima K: Phase I study of sorafenib in Japanese
patients with hepatocellular carcinoma. Cancer Sci. 99:159–165.
2008.PubMed/NCBI
|
|
5
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tomizawa M, Shinozaki F, Sugiyama T,
Yamamoto S, Sueishi M and Yoshida T: Sorafenib suppresses the cell
cycle and induces the apoptosis of hepatocellular carcinoma cell
lines in serum-free media. Exp Ther Med. 1:863–866. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Okuyama H, Ikeda M, Kuwahara A, Takahashi
H, Ohno I, Shimizu S, Mitsunaga S, Senda S and Okusaka T:
Prognostic factors in patients with hepatocellular carcinoma
refractory or intolerant to sorafenib. Oncology. 88:241–246. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan
H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular,
cellular and microenvironmental mechanism of sorafenib resistance
in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ye L, Yang X, Guo E, Chen W, Lu L, Wang Y,
Peng X, Yan T, Zhou F and Liu Z: Sorafenib metabolism is
significantly altered in the liver tumor tissue of hepatocellular
carcinoma patient. PLoS One. 9:e966642014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vaitheesvaran B, Xu J, Yee J, Q-Y L, Go
VL, Xiao GG and Lee WN: The Warburg effect: A balance of flux
analysis. Metabolomics. 11:787–796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Leffert HL and Paul D: Studies on primary
cultures of differentiated fetal liver cells. J Cell Biol.
52:559–568. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Matsumoto K, Yamada K, Kohmura E,
Kinoshita A and Hayakawa T: Role of pyruvate in ischaemia-like
conditions on cultured neurons. Neurol Res. 16:460–464. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holden HM, Thoden JB, Timson DJ and Reece
RJ: Galactokinase: Structure, function and role in type II
galactosemia. Cell Mol Life Sci. 61:2471–2484. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wheatley DN, Scott L, Lamb J and Smith S:
Single amino acid (arginine) restriction: Growth and death of
cultured HeLa and human diploid fibroblasts. Cell Physiol Biochem.
10:37–55. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohira RH, Dipple KM, Zhang YH and McCabe
ER: Human and murine glycerol kinase: Influence of exon 18
alternative splicing on function. Biochem Biophys Res Commun.
331:239–246. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ai Y, Jenkins NA, Copeland NG, Gilbert DH,
Bergsma DJ and Stambolian D: Mouse galactokinase: Isolation,
characterization, and location on chromosome 11. Genome Res.
5:53–59. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Phillips JW, Jones ME and Berry MN:
Implications of the simultaneous occurrence of hepatic glycolysis
from glucose and gluconeogenesis from glycerol. Eur J Biochem.
269:792–797. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sumida KD, Crandall SC, Chadha PL and
Qureshi T: Hepatic gluconeogenic capacity from various precursors
in young versus old rats. Metabolism. 51:876–880. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tomizawa M, Toyama Y, Ito C, Toshimori K,
Iwase K, Takiguchi M, Saisho H and Yokosuka O: Hepatoblast-like
cells enriched from mouse embryonic stem cells in medium without
glucose, pyruvate, arginine, and tyrosine. Cell Tissue Res.
333:17–27. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tomizawa M, Shinozaki F, Sugiyama T,
Yamamoto S, Sueishi M and Yoshida T: Survival of primary human
hepatocytes and death of induced pluripotent stem cells in media
lacking glucose and arginine. PLoS One. 8:e718972013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO,
Zheng BJ and Guan XY: Identification and characterization of
tumorigenic liver cancer stem/progenitor cells. Gastroenterology.
132:2542–2556. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reynolds BA and Weiss S: Clonal and
population analyses demonstrate that an EGF-responsive mammalian
embryonic CNS precursor is a stem cell. Dev Biol. 175:1–13. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rappa G, Mercapide J, Anzanello F,
Prasmickaite L, Xi Y, Ju J, Fodstad O and Lorico A: Growth of
cancer cell lines under stem cell-like conditions has the potential
to unveil therapeutic targets. Exp Cell Res. 314:2110–2122. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim J, Jung J, Lee SJ, Lee JS and Park MJ:
Cancer stem-like cells persist in established cell lines through
autocrine activation of EGFR signaling. Oncol Lett. 3:607–612.
2012.PubMed/NCBI
|
|
26
|
Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang
R, Li J, Zhang Y, Chen L, Qian H, et al: Sphere-forming cell
subpopulations with cancer stem cell properties in human hepatoma
cell lines. BMC Gastroenterol. 11:712011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nakamura T, Teramoto H, Tomita Y and
Ichihara A: L-proline is an essential amino acid for hepatocyte
growth in culture. Biochem Biophys Res Commun. 122:884–891. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Davies B and Fried M: The L19 ribosomal
protein gene (RPL19): Gene organization, chromosomal mapping, and
novel promoter region. Genomics. 25:372–380. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Olszewski U, Liedauer R, Ausch C,
Thalhammer T and Hamilton G: Overexpression of CYP3A4 in a COLO 205
Colon Cancer Stem Cell Model in vitro. Cancers (Basel).
3:1467–1479. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pang RW and Poon RT: Cancer stem cell as a
potential therapeutic target in hepatocellular carcinoma. Curr
Cancer Drug Targets. 12:1081–1094. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Simons AL, Mattson DM, Dornfeld K and
Spitz DR: Glucose deprivation-induced metabolic oxidative stress
and cancer therapy. J Cancer Res Ther. 5:(Suppl 1). S2–S6. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang D, Li J, Wang F, Hu J, Wang S and
Sun Y: 2-Deoxy-D-glucose targeting of glucose metabolism in cancer
cells as a potential therapy. Cancer Lett. 355:176–183. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Phillips MM, Sheaff MT and Szlosarek PW:
Targeting arginine-dependent cancers with arginine-degrading
enzymes: Opportunities and challenges. Cancer Res Treat.
45:251–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
